Scarica l'app Stockscreener
1.93
0.00%
0.00
Propanc Biopharma Inc Borsa (PPCB) Ultime notizie
Nasdaq most active stocks: - MSN
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Surges 80% as Trading Volume SpikesVOLD Alert - newsline.com
PPCB stock surges over 200% just days after implementing reverse share split – what’s driving today’s smashing rally? - MSN
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
Trending Industry Today: Propanc Biopharma Leads Gains In Crypto Treasury Stocks - Moomoo
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. - ChartMill
These stocks are the most active in today's session - ChartMill
PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally? - Asianet Newsable
Clinical-Stage Biotech Rockets 308% After $5M Buyback and Phase 1 Cancer-Trial Path - The Globe and Mail
Propanc Biopharma authorizes $5M share buyback program; shares surge - MSN
Propanc Biopharma, Inc. authorizes a Buyback Plan. - marketscreener.com
Propanc Biopharma, Inc. announces an Equity Buyback for $5 million worth of its shares. - marketscreener.com
Propanc Biopharma rockets after announcing $5M share repurchase program - Quiver Quantitative
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React - TechStock²
Propanc Biopharma Authorizes $5 Million Stock Buyback Program; Shares Jump - marketscreener.com
Trending Stocks Today | Propanc Biopharma Surges 282.95% - Moomoo
PPCB Stock Explodes As PRP Trial Plans Heat Up - StocksToTrade
PPCB Stock Pops As Propanc Biopharma Advances PRP Trials - timothysykes.com
Propanc Biopharma authorizes $5 million stock buyback program - Investing.com
Propanc Biopharma authorizes $5 million stock buyback program By Investing.com - Investing.com Australia
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program - The Manila Times
Cancer-drug developer Propanc sets aside $5M to buy its own stock - Stock Titan
Morning Market Movers: GLXG, PPCB, DSY, VSME See Big Swings - RTTNews
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise - Sahm
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain - markets.businessinsider.com
Propanc Biopharma's CEO Attends Keynote Address on Aging Science at University of Granada Event - Quiver Quantitative
How an ageing-science keynote ties into Propanc’s cancer trial - Stock Titan
Propanc Biopharma’s CEO Attends Keynote Address, 'Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain - The Manila Times
PPCB - Finviz
PPCB News | PROPANC BIOPHARMA INC (NASDAQ:PPCB) - ChartMill
Propanc Biopharma (PPCB) Edges Lower Amid Biotech VolatilityBreakout Confirmation - thelegaladvocate.com
Propanc Biopharma (PPCB) Holds Near Support as Slight Decline Signals CautionSuperTrend Flip - The Legal Advocate
PPCB Stock Price, Quote & Chart | PROPANC BIOPHARMA INC (NASDAQ:PPCB) - ChartMill
Propanc Biopharma (PPCB) Earnings Outlook: Key Metrics for Q3 2025Post-Announcement Reaction - Newser
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade - The Manila Times
Propanc Biopharma to file CTA in Australia for phase 1b study in 30-40 advanced cancer patients - marketscreener.com
Propanc Biopharma, Inc. CEO Forecasts Medical Breakthroughs Against Pancreatic Cancer Over Next Decade - Quiver Quantitative
Propanc pancreatic cancer drug saw 3 of 4 patients outlive life expectancy - Stock Titan
Propanc engages CDMO for GMP manufacture of cancer drug PRP By Investing.com - Investing.com Australia
Propanc engages CDMO for GMP manufacture of cancer drug PRP - Investing.com UK
Propanc Biopharma engages European CDMO for GMP production of PRP - TipRanks
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 3040 Advanced Cancer Patients - The Manila Times
Once-weekly proenzyme cancer therapy nears first tests in humans - Stock Titan
Propanc Biopharma (PPCB) Stock: Up +21.18%, Key Resistance at $2.16 2026-05-18Sector Analysis - newser.com
Propanc Biopharma (PPCB) Stock: Up +20.59%, Key Resistance at $2.15 2026-05-18Advance Decline Volume - The Legal Advocate
Propanc Biopharma, Inc. (PPCB) stock price prediction 2026–2030 - Bitget
Propanc Biopharma reports Q3 results, secures financing - Investing.com UK
Propanc Biopharma reports Q3 results, secures financing By Investing.com - Investing.com Nigeria
Propanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate Developments - Quiver Quantitative
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results - marketscreener.com
1.79%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):